

**North of Tyne
Area Prescribing Committee**
www.northoftyneapc.nhs.uk
Tuesday 9th July 2013.
**Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt
Business Park.**
The meeting will start at 12:30pm

AGENDA

1. Apologies for absence
2. Declarations of interest
 - Relevant declarations
3. Appeals against previous decisions
 - None
4. Decision summary from the meeting held on 14/5/13. Email 23/5/13
 Revised minutes from the meeting held on 14/5/13. Enclosed with agenda
5. Matters arising/actions from previous meeting Email 5/7/2013
 - 2013/34 – notes from meeting relating to Apixiban
6. Report from the Formulary sub-group Enclosed with agenda
 - Draft minutes from meeting held on 17/6/13 Enclosed with agenda
 - Decision summary from meeting held on 17/6/13 Available on website
 - Formulary version 4.4 May 2013
7. Report from the Medicines Guidelines and Use Group Enclosed with agenda
 - Draft minutes from 19/6/13 Enclosed with agenda
 - Terms of reference for approval Enclosed with agenda
 - Infant milk guideline Enclosed with agenda
 - Prescribing Guidelines for Stoma Accessories (Adult) Enclosed with agenda
 - Traffic Light List version 4.0 May 2013 Available on website
8. Report from the Antimicrobial Chemotherapy Sub-group
 - No report due
9. Documents previously circulated by e-mail
 - None
10. Terms of reference – Revised – Draft for discussion Enclosed with agenda

11. Buccal Midazolam Enclosed with agenda

12. Erectile Dysfunction Enclosed with agenda

13. NICE Technology Appraisals published in May and June
 - TA283 - Macular oedema (retinal vein occlusion) - ranibizumab
 - TA284 - Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer - negative appraisal
 - TA285 - Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab - negative appraisal
 - TA286 - Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal due to lack of submission)
 - TA287 - Pulmonary embolism and recurrent venous thromboembolism – rivaroxaban
 - TA288 - Type 2 diabetes - Dapagliflozin combination therapy
 - TA289 - Myelofibrosis (splenomegaly, symptoms) - ruxolitinib - negative appraisal.
 - TA290 - Overactive bladder - mirabegron
 - TA291 - Gout (tophaceous, severe debilitating, chronic) – pegloticase - Negative appraisal.

14. Chairman's action
 - None

15. Any other business

16. Date and time of next meeting:
Tuesday 10th September 2013
Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park, North Tyneside.
The meeting will start at 12:30pm